Novel, innovative, and targeted medicines to improve outcomes for cancer patients
Amplifying success in immunotherapy
Novel, innovative, targeted medicines
When harnessed appropriately, the immune system is an extremely potent and specific endogenous anti-tumor mechanism. Our mission is to develop novel, innovative and targeted medicines that augment endogenous anti-tumor immunity to improve outcomes for patients affected by cancer.
Pio Tx’s team brings decades of global scientific and commercial expertise, with proven success in therapeutic discovery, preclinical, clinical, regulatory and commercial stages of drug development.
MD PhD FRACS MBA
Chief Executive Officer & Managing Director
Chief Scientific Officer
BSc Grad Cert BA
Chief Operating Officer & Company Secretary
Immunotherapy has revolutionised cancer treatment, however there are challenges to its efficacy.
Pio Tx is developing novel cancer immunotherapies to overcome clinical challenges, to facilitate enhanced combinatorial approaches, and to improve outcomes for patients.